WooGene B&G Co., Ltd (KOSDAQ:018620)

South Korea flag South Korea · Delayed Price · Currency is KRW
990.00
+3.00 (0.30%)
At close: Jul 11, 2025, 3:30 PM KST
-9.59%
Market Cap 28.60B
Revenue (ttm) 53.93B
Net Income (ttm) -5.07B
Shares Out 28.89M
EPS (ttm) -176.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 26,397
Average Volume 39,326
Open 997.00
Previous Close 987.00
Day's Range 981.00 - 997.00
52-Week Range 823.00 - 1,127.00
Beta 0.52
RSI 64.15
Earnings Date Aug 13, 2025

About WooGene B&G

WooGene B&G Co., Ltd. engages veterinary medicines, microbial technology, and vaccines business in South Korea and internationally. It offers antibiotic, vaccine, nutrient, anti-inflammation, metabolic stimulant, and iron supplement products for swine, poultry, cattle, aquatic animals, companion animals, and raw materials, as well as operates vaccine research center. The company was formerly known as WooJin Co., Ltd. and changed its name to WooGene B&G Co., Ltd. in March 2001. WooGene B&G Co., Ltd. was founded in 1977 and is headquartered in Hw... [Read more]

Industry Pharmaceutical Preparations
Founded 1977
Employees 84
Stock Exchange KOSDAQ
Ticker Symbol 018620
Full Company Profile

Financial Performance

In 2024, WooGene B&G's revenue was 55.68 billion, a decrease of -3.87% compared to the previous year's 57.92 billion. Losses were -5.22 billion, 341.0% more than in 2023.

Financial Statements

News

There is no news available yet.